Does Medicare Cover Tirzepatide (Mounjaro/Zepbound)? — 2026 Guide

"Does Medicare cover tirzepatide?" has one of the most counterintuitive answers in all of prescription coverage: it depends almost entirely on which condition you're being treated for, not on the drug itself. The same molecule — tirzepatide — is sold as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea, and Medicare treats those indications very differently. This guide explains the statutory rule that blocks weight-loss coverage, the two indications that can unlock it, why Medicare beneficiaries can't use the manufacturer savings card, and the 2026 pricing developments that are changing the cash-pay math. This is policy information current as of June 2026, not insurance or medical advice — Part D formularies and federal rules change, and your own plan documents are the only authority on your coverage.

The core rule: Medicare cannot cover drugs used for weight loss

The starting point is a decades-old statute. Medicare Part D is legally prohibited from covering drugs when they are used for weight loss — a coverage exclusion written into the law that created the Part D benefit. That single rule is why a drug as effective as Zepbound, FDA-approved for obesity, is not a covered Part D benefit for that purpose. It isn't a formulary choice your plan made; it's a federal statutory exclusion that applies across Medicare. So if you're seeking tirzepatide purely for weight management, the default Medicare answer is no — and no appeal or prior-authorization form changes a statutory exclusion.

The indications that can flip the answer to yes

The exclusion is about the use, not the molecule — which is exactly why the indication matters so much:

Type 2 diabetes (Mounjaro). When tirzepatide is prescribed as Mounjaro for type 2 diabetes, it is being used for a covered medical condition, not weight loss — so Medicare Part D plans can and frequently do cover it, subject to the plan's formulary placement, prior authorization, and cost-sharing. Mounjaro's pivotal SURPASS diabetes trials and its glucose-lowering plus weight effects are well established, and diabetes is squarely within Part D's scope. This is the most common route by which Medicare beneficiaries get tirzepatide covered.

Obstructive sleep apnea (Zepbound). This is the newer and more important wrinkle. In late 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, on the strength of the SURMOUNT-OSA trial, which showed tirzepatide substantially reduced sleep-apnea severity (the apnea-hypopnea index) compared with placebo¹. Because OSA is a covered medical condition rather than "weight loss," that approval created a path for Part D coverage of Zepbound for the OSA indication — and CMS has signaled that plans may cover Zepbound when prescribed for OSA in eligible patients. We cover this indication in depth in our guide to Zepbound for sleep apnea. The catch: you have to actually have qualifying OSA, with the documentation to support it; obesity alone does not unlock this door.

The savings-card lockout that pushes beneficiaries to cash

Here's the trap that catches many people newly on Medicare. Eli Lilly's manufacturer savings card — the discount that can bring commercially-insured patients' cost down to as little as $25/month — excludes anyone enrolled in a government program: Medicare, Medicaid, the VA and TRICARE are all ineligible. So a Medicare beneficiary whose plan won't cover Zepbound for weight loss also can't use the savings card to soften the blow. That double bind is the reason so many Medicare-age patients end up paying cash through the self-pay route described below. (For the commercial-insurance picture and the savings card mechanics, see our does insurance cover Zepbound guide.)

The cash route — and the 2026 pricing shift

If Medicare won't cover your tirzepatide (the typical situation for a weight-loss indication), the practical fallback is Eli Lilly's LillyDirect self-pay program, which sells brand Zepbound single-dose vials at roughly $299–$449 per month depending on dose (prices effective February 23, 2026; a 28-day, 4-vial supply): about $299 for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 mg and higher. Because the savings-card lockout doesn't apply to a straight cash purchase, self-pay vials are the most common legitimate path for Medicare beneficiaries seeking the drug for weight management.

Separately, 2026 has brought policy movement aimed at lowering GLP-1 cash prices through direct government-negotiated and direct-to-consumer arrangements (commonly discussed under the TrumpRx banner), which have been reported to drive certain GLP-1 cash prices toward a much lower monthly figure for eligible buyers. These arrangements are evolving and the exact terms, eligible products and timing have shifted as they roll out — so treat any specific low headline number as something to verify at the point of purchase, not a guaranteed Medicare benefit. The durable, checkable benchmark remains the LillyDirect self-pay vial pricing above. For the full cash-price landscape — list price, coupons, vials vs pens — see our Zepbound cost and savings guide and our Zepbound vials vs pens self-pay breakdown.

How to find out what YOUR plan does

Because the answer turns on indication and plan formulary, the fastest way to get a real answer is to ask three specific questions of your Part D plan (the number is on your card):

1. 1.Is Mounjaro covered for type 2 diabetes on this plan's formulary, and on what tier / with what prior authorization?
2. 2.Is Zepbound covered for obstructive sleep apnea, and what documentation does the prior authorization require?
3. 3.What is my cost-sharing at each tier, and does the drug fall under any deductible phase?

If you're being treated for weight loss alone, expect the answer to be no under the statutory exclusion — in which case the self-pay route is the realistic path. If you have diabetes or qualifying OSA, the answer can be yes, and the work shifts to clearing prior authorization with the right documentation.

Does the drug justify the effort? What the evidence says

Tirzepatide's results are why people fight this coverage maze at all. In the 72-week SURMOUNT-1 obesity trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo²; head-to-head against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%³. And it's a long-term medication: in SURMOUNT-4, people who stopped regained substantial weight while those who continued kept losing⁴, which is exactly why ongoing coverage (or an affordable ongoing cash price) matters so much. For the full benefit-and-risk picture see our tirzepatide evidence guide, and for vetted ways to access the drug, our best tirzepatide providers overview and best place to get Zepbound online roundup.

The honest bottom line

Does Medicare cover tirzepatide? For weight loss, no — a federal statute bars Part D from covering drugs used for weight loss, and the savings card is off-limits to Medicare beneficiaries too. For type 2 diabetes (Mounjaro), usually yes, subject to your plan's formulary and prior authorization. For obstructive sleep apnea (Zepbound), increasingly yes, following the 2024 OSA approval, if you have qualifying, documented OSA. When coverage isn't available, the realistic path is LillyDirect self-pay vials at ~$299–$449/month, with 2026 direct-purchase policy developments potentially lowering cash prices further — verify those at the point of purchase rather than assuming them.